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ABSTRACT
MicroRNAs (miRNAs) have negative effects on gene
expression and are major players in cell function
in normal and pathological conditions. Epstein-Barr
virus (EBV) infection of resting B lymphocytes re-
sults in their growth transformation and associates
with different B cell lymphomas. EBV-mediated B cell
transformation involves large changes in gene ex-
pression, including cellular miRNAs. We performed
miRNA expression analysis in growth transformation
of EBV-infected B cells. We observed predominant
downregulation of miRNAs and upregulation of a
few miRNAs. We observed similar profiles of miRNA
expression in B cells stimulated with CD40L/IL-4,
and those infected with EBNA-2- and LMP-1-deficient
EBV particles, suggesting the implication of the NF-
kB pathway, common to all four situations. In fact, the
NF-kB subunit p65 associates with the transcription
start site (TSS) of both upregulated and downregu-
lated miRNAs following EBV infection This occurs
together with changes at histone H3K27me3 and hi-
stone H3K4me3. Inhibition of the NF-kB pathway im-
pairs changes in miRNA expression, NF-kB binding
and changes at the above histone modifications near
the TSS of these miRNA genes. Changes in expres-
sion of these miRNAs also occurred in diffuse large
B cell lymphomas (DLBCL), which are strongly NF-
kB dependent. Our results highlight the relevance of
the NF-kB pathway in epigenetically mediated miRNA
control in B cell transformation and DLBCL.
INTRODUCTION
The Epstein-Barr virus (EBV) is one of the best studied
oncogenic human herpesvirus. The vast majority of the hu-
man population is infected by EBV. Fortunately, the most
common pattern of EBV infection is a clinically silent child-
hood infection and, generally, EBV establishes a perma-
nent latent infection without further complications. How-
ever, EBV has oncogenic potential, reflected by its ability
to growth transform B lymphocytes in vivo. EBV is asso-
ciated with different tumors, including several B cell lym-
phomas, and carcinomas of the stomach and the nasopha-
ryngeal cavity. EBV is considered to play a causative role in
Burkitt lymphomas although the mechanism remains elu-
sive (1). EBV has a less strict association with Hodgkin’s
lymphoma and diffuse large B cell lymphoma (DLBCL).
However, the great prevalence of these latter two lymphoma
types makes the study of the changes associated with EBV
infection of B-cells and biology particularly relevant to our
understanding of lymphoma pathogenesis.
In vitro, EBV efficiently immortalizes primary resting
B lymphocytes (RBLs), converting them into permanently
growing lymphoblastoid cell lines (LCLs). In vitro infec-
tion results in the activation of a specific viral gene expres-
sion program that involves expression of six nuclear anti-
gens (EBNA-1, -2, 3A, -3B, -3C and -LP), three membrane
proteins (LMP-1, -2A and -2B) and a set of 25 microRNAs
(miRNAs). Five of these proteins and several of the miR-
NAs are essential for transformation. For instance, LMP-1
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is required to establish cell transformation in vitro (2) and
is required for continuous proliferation (3). It has also been
reported that members of the EBV miRNA cluster cooper-
ate to transform B lymphocytes (4). Infection of B cells with
EBV is similar to the physiological stimulation with CD40L
plus IL-4 (5), T cell-derived mitogens and in both cases in-
volves the activation of the NF-kB pathway. Dissection of
the cell pathways has shown that EBV can also make use of
the NF-kB pathway through LMP-2A in EBV-associated
epithelial carcinoma (6) and it is likely that LMP-2A could
have similar effects following infection of B cells.
EBV-mediated growth-transformation of B cells results
in major changes in gene expression and nuclear reor-
ganization. Changes in gene expression levels depend on
a variety of mechanisms including not only transcription
factor-mediated and epigenetic control (7) but also post-
transcriptional regulation, such as those dependent on viral
but also cellular miRNAs. We and other researchers have
previously investigated the effects of experimental infection
with EBV on epigenetic marks. For instance, EBV infection
leads to demethylation of genes within the B cell transcrip-
tion program (8) and contributes to the overexpression of
genes essential for transformation. Also, analyses of histone
modifications have shown that EBV infection results in both
global and gene-specific changes in different modifications,
which also contribute to key changes in gene expression dur-
ing the growth-transformation of B cells (9).
MicroRNAs are a class of non-coding genes with
broad influences on cellular signal transduction pathways.
They function by inhibiting translation of select groups
of mRNA transcripts containing imperfect annealing se-
quences in their 3′ untranslated regions (3′ UTRs) and, less
frequently, through other regions of the transcript. Previous
studies have shown that EBV infection results in upregula-
tion of several miRNAs. For instance, miR-34a is strongly
induced by EBV (10) and is associated with growth pro-
motion. It has also been demonstrated that miR-155 is up-
regulated following EBV infection. These miRNAs are also
strongly upregulated in B cell lymphomas (11,12) and it has
been proposed that miRNAs misregulation in lymphomas
could be used for diagnosis, prognosis or prediction of re-
sponse to specific therapies (13). As aforementioned, DL-
BCL is one of the B cell lymphoma types associated with
EBV (14) and also the most common type of lymphoma,
accounting for 30–40% of lymphomas in western countries.
On the basis of the correlation between microarray gene ex-
pression profiling and clinical outcome, it is now possible
to classify the majority of DLBCLs into molecular vari-
ants called activated B cell-like DLBCL (ABC-DLBCL)
and germinal center-like DLBCL (GC-DLBCL). A distin-
guishing feature of DLBCL is a signature of genes that are
induced by NF-kB, which is upregulated in ABC-DLBCL
(15) but not in GC-DLBCL.
We currently know little about the overall relevance of
miRNAs in EBV-mediated transformation of B cells and
about how much of the miRNA expression footprint in
B cell lymphomas is associated with EBV primary in-
fection. In this study, we investigated the deregulation
of human miRNAs during EBV-mediated transformation
of RBLs to LCLs, using a high-throughput strategy. We
observed significant upregulation of several miRNAs, al-
though miRNA downregulation was highly predominant.
Time-course analysis indicated that miRNA deregulation
occurs before cell proliferation, particularly for those that
become upregulated. Also, analysis of B cells infected with
EBV deficient in EBNA-2 and LMP-1, and with B cells
stimulated with IL-4/CD40L, revealed that similar changes
in miRNA expression occur, suggesting a potential role of
the stimulation of the NF-kB pathway that is common to
all these conditions. We showed that changes in miRNA ex-
pression occur in parallel with changes in histoneH3K4me3
and H3K27me3. The involvement of NF-kB in miRNA
deregulation was demonstrated by the enrichment of the
binding motifs of the NF-kB complex subunits among the
genomic sequences of the miRNAs undergoing expression
changes, NF-kB p65 binding to miRNA promoters from
ChIP-seq data and the finding that p65 binds the promoters
of miRNAs following EBV infection.Moreover, we showed
that the use of NF-kB inhibitors impairs the expression
changes of these miRNAs, and abrogates both the associ-
ation of the NF-kB subunit p65 as well as changes in his-
tone modifications near the transcription start site (TSS) of
these miRNAs.We also observed a large overlap in miRNA
expression changes when comparing the profiles associated
with EBV-mediated transformation of B cells with the pro-
files obtained forDLBCLprimary samples.miRNAexpres-
sion changes are related to changes in the levels of targets
relevant to B cell transformation and in DLBCL. Our find-
ings identify a novel mechanistic link between NF-kB and
epigenetic regulation of miRNAs in EBV-mediated trans-
formation of B cells and their implications in this model and
in DLBCLs.
MATERIALS AND METHODS
Ethics statement
Human blood samples used in this study came from anony-
mous blood donors and were obtained from the Catalan
blood donation center (Banc de Sang i Teixits). The anony-
mous blood donors received oral and written information
about the possibility that their blood would be used for re-
search purposes, and any questions that arose were then an-
swered. Before giving their first blood sample the donors
signed a consent form at the Banc de Teixits, which ad-
heres to the principles set out in the WMA Declaration of
Helsinki. The protocol used to transform B cells from these
anonymous donors with EBV was approved by IDIBELL’s
Committee of Biosecurity (CBS) on 5 May 2011 and the
Ethics Committee of the University Hospital of Bellvitge
(CEIC) on 28 May 2011.
The study population consisted of a retrospective series
of de novo cases of DLBCL obtained from various centers
in Spain. The study was reviewed and approved as being of
minimal or no risk or as being exempt by each of the partic-
ipating institutional review boards, and the overall collabo-
rative study was approved by the institutional review board
of the Spanish National Cancer Research Centre (CNIO),
Madrid, Spain. The study protocol and sampling methods
were approved by the Instituto de Salud Carlos III insti-
tutional review board in de-identified anonymous format.
All cases positively stained for CD20. Cases diagnosed as
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T cell histiocyte-rich B cell lymphoma, primary mediasti-
nal B cell lymphoma cases, cutaneous LBCL, intravascular
LBCL and those histologically associated with a follicular
lymphoma component were excluded.
Cells
Viable peripheral blood mononuclear cells were isolated
by Lymphoprep density gradient centrifugation from buffy
coats from anonymous blood donors. Resting B cells were
isolated by positive selection using CD19MicroBeads (Mil-
tenyi Biotec), or by depletion using a B Cell Isolation Kit
(Miltenyi Biotec). For EBV-mediated transformation, iso-
lated B cells were immortalized with the supernatant of
the marmoset cell line B95.8 and with the EBV variant
2089 made from 293 cells carrying a recombinant B95.8
EBV genome (16). Preparations of the 2089 recombinant
wild-type EBV with a GFP (green fluorescent protein) vin-
sert or viruses deleted for LMP-1 and EBNA-2 (17) were
made from 293 cells carrying the recombinant B95.8 EBV
genomes, and transfected with 0.5 g BZLF1 (p509) +
0.5 g gp110 (pRA). For B cell activation, isolated B cells
were cultured 5 × 106/3 ml per well of a 6-well plate with
50 ng/ml CD40L (Enzo Life Sciences) and 50 ng/ml IL-4
(Gentaur) and the B cell blasts were split weekly in a 1:2
ratio. The percentages of activated and proliferating B-cells
were detected byCD86 expressionmeasured by flow cytom-
etry and tritiated thymidine incorporation, respectively.
miRNA profiling and individual assays
For the miRNA expression analysis, cDNA synthesis and
real-time quantitative polymerase chain reaction (qPCR)
were performed using the miRCURY LNA Universal RT
microRNA PCR system (Exiqon, Denmark) according to
the manufacturer’s instructions. miRNAs were screened us-
ing Ready-to-Use microRNA PCR Human Panel I V2.R
from Exiqon. For each reverse transcriptase-PCR (RT-
PCR) reaction, 30 ng of total RNA were used. Samples
from RBLs and LCLs were analyzed in triplicates on a
Roche LightCycler 480 real-time PCR system. Results were
converted to relative values using the inter-plate calibrators
included in the panels (log 2 ratios). Samples with Cp val-
ues equal or higher than 37 were considered as having the
same value (i.e. 37 Cp), considering that above that thresh-
old the amount of a particular miRNA is negligible. RBL
and LCL average expression values were normalized with
respect to the reference miRNAmiR-103. Differentially ex-
pressed miRNAs (log FC > 2 or log FC < −2) were se-
lected. Individual assays were also performed using probes
from Exiqon. Nucleolar RNAs RNU44 and RNU48 were
used for frozen samples assays.
Quantitative RT-PCR (qRT-PCR)
For qRT-PCR of cellular genes, cDNA was produced with
the SuperScript II Reverse Transcriptase (Invitrogen Co).
Quantitative real-time PCR was done on a LightCycler 480
II System using LightCycler 480 SYBRGreenMix (Roche).
Reactions were carried out in triplicate and qRT-PCR data
were analyzed using the standard curve method. We used
the housekeeping gene RPL38 and HPRT1 as a control. All
primer sequences are listed in Supplementary Table S1.
Chromatin immunoprecipitation (ChIP) assays
To test the binding of p65 NF-kB to miRNA promot-
ers, as well as changes in histone H3K4me3 and histone
H3K27me3, we performed ChIP assays as previously de-
scribed (18). We used a rabbit polyclonal against the C-t
of NF-kB p65 (sc-372, Santa Cruz Biotechnology), anti-
histone H3K4me3 (17–614, Millipore) and anti-histone
H3K27me3 (07–449, Millipore). Immunoprecipitated ma-
terial was used for analyses of specific sequences by qRT-
PCR (see primers sequences in Supplementary Table S1).
DNA methylation analysis
Bisulfite pyrosequencing (BPS) was performed according
to standard protocols and evaluated with the Pyro Q-
CpG 1.0.9 program (Biotage, Uppsala, Sweden). Primer se-
quences for BPS PCR reactions are shown in Supplemen-
tary Table S1.
ChIP-seq analysis
ChIP-seq sources and data processing. Sources of ChIP-
seq data are detailed in Supplementary Table S2. We down-
loaded either aligned BEDor BAM format files from public
databases. BAM files were converted to BED format using
BETools (bamToBed function) (19). When there was more
than one replicate, they were concatenated to obtain wider
coverage and greater sequence depth.
Analysis of differential association of histone modifications.
Differential association (increased or decreased genomic lo-
cation) of H3K4me3, H3K27me3 and H3K9me3 was ana-
lyzed using the MACS program (version 2.0.9; macs2diff
function) (20) using the parameter settings: -g hs -nomodel
-shiftsize= 75 -bdg -a 4 -q 0.005. Therefore, the q-value cut-
off was established as 0.005. MACS’ macs2diff function es-
tablishes differential regions by comparing two treatment
files corresponding to two conditions (in this case, lym-
phoblastoid cells and resting B cells), and comparing each
of them against corresponding control ‘Input’ files. This
comparison generates an output containing a list of ‘differ-
entially bound locations’ with a ‘differential score’ (−log10
q-value), where a positive number means that the signal in
lymphoblastoid cells is higher than in resting B cells, and
a negative number means the opposite. Higher scores indi-
cate a greater difference between the two cell types. Unique
and consistently found differentially bound locations were
considered for further analysis, e.g. correlation with expres-
sion. However, differential locations with a score (−log10 q-
value) of exactly zerowere excluded from the analysis.When
more than one replicate of the aligned file was present, they
were merged to ensure wider coverage and greater sequenc-
ing depth. Significantly differentially bound locations were
annotated to the closest EnsEMBL (version-65) transcripts
and genes (21) using BEDTools (closestBed function) (19).
We calculated the Pearson’s correlation coefficient between
the differentially bound location scores, in which negative
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and positive values respectively indicate decreased and in-
creased location scores in lymphoblastoid cells/resting B
cells comparisons. Normalized read density wig files were
produced using JavaGenomics Toolkit (http://palpant.us/
java-genomics-toolkit/) andwere used inUCSC (University
of California, Santa Cruz) genome browser (http://genome.
ucsc.edu/) to visualize read-density peaks around miRNA
TSS.
Transfection with miRNA mimics and siRNAs
A total of 5 nM miRNA mimics (Ambion) were trans-
fected into LCLs using Lipofectamine RNAiMAX reagent
(Invitrogen) following the manufacturer’s protocol. Exper-
iments were also performed using 5 nM control mimic. To
silence p65, we used Silencer Select Pre-Designed siRNA
(Life Technologies) against human RELA (p65), targeting
exon 11 (ref. s11916) in parallel with a Silencer Select neg-
ative control in purified CD19+ cells, followed by addi-
tion of the EBV-containing supernatant 4 h after the cells
were transfected with the siRNA. We used Lipofectamine
RNAiMAX Transfection Reagent (Invitrogen) for efficient
siRNA transfection. mRNA and protein levels were ex-
amined by qRT-PCR and western blot 2 and 3 days after
siRNA transfection.
Cell proliferation and apoptosis assays
To test the effects of transfection of specific mimics on
DNA synthesis, we measured incorporation of 5′-bromo-
2′-deoxyuridine (BrdU) 48 h after miRNA transfection.
Cells were incubated in 15 M BrdU during 30 min. Cells
were fixed with 70% ethanol 1 h and permeabilized (phos-
phate buffered saline (PBS)-bovine serum albumin-Triton
X-100 0.8% (PBT), 10 min, RT) and treated with 2 M HCl
for 30 min, After DNA opening, HCl was neutralized by
two 5-min washed with NaBo (0.1 M, pH 8.5) and two
5-min washes with PBT. Cells were incubated with anti-
BrdU antibody (18 h at 4C, 1:1000 dilution) and anti-
mouse Alexa-488 conjugated antibody was added to vi-
sualize the BrdU-positive nuclei. Cells were analyzed us-
ing fluorescence-activated cell sorting (FACS) (Beckman
Coulter) and FlowJo software (Tree Star, Inc.). We also
measured [3H]-thymidine incorporation, 48 h after miRNA
transfection, cells were pulsed with 1 ml [3H]-thymidine
(0.4 mCi/ml) for 4 h at 37C◦. After washing three times
with PBS, cells were incubated with 1 ml ice-cold 5%
trichloroacetic acid (TCA) for 15 min at 4C◦, washed three
times with absolute methanol, air dried and the TCA-
precipitable fraction was solubilized in 500 ml of 0.1 M
NaOH-1% sodium dodecyl sulphate. [3H]-thymidine incor-
poration was determined with a scintillation counter. We
used tetramethylrhodamine methyl ester (TMRM) to mea-
sure apoptosis. Forty eight hours after transfection with
mimics, cells were incubated during 4 hwith etoposide. Cells
were washed two times with PBS and incubated 30 min at
37C◦ with TMRM. Cells were analyzed using FACS (Beck-
man Coulter) and FlowJo software (Tree Star, Inc.).
Differential analysis from expression beadchips
Expression data were downloaded from NCBI (National
Center for Biotechnology Information) GEO database (22)
with accession number GSE30196 (23). Authors investi-
gated global gene expression profiles in peripheral blood;
hence, in this paper we focused on the samples of LCLs,
and CD19-specific B cell subsets. Data analysis was per-
formed on statistical environment R (24), using Bioconduc-
tor Package Genefilter with the purpose of applying non-
specific filtering by IQR (interquartile range). Then first,
processed data was utilized directly, the threshold for IQR
was set to 0.5 and a Welch’s t-test was carried out. Subse-
quently, data were selected taking a cut-off ofP-value below
0.01, FDR (False Discovery Rate) below 0.05 and establish-
ing fold-change value above 1.4 for overexpressed data and
below 1/1.4 for downregulated genes.
miRNA target prediction
To predict the potential targets of the dysregulated miR-
NAs, we used the algorithms available inmiRWalk database
(25), including information produced by eight established
miRNA prediction programs on 3′ UTRs of all known
genes of Human: RNA22, miRanda, miRDB, TargetScan,
RNAhybrid, PITA, PICTAR and Diana-microT. Only
those targets predicted by at least three databases were con-
sidered for further analysis.
Differential expression analysis of microRNA microarrays
Microarray Expression data are Agilent Human Mi-
croRNA microarray and come from a study by Martin-
Pe´rez et al. (26) and data for lymph nodes (LN) (GSE23026)
from the same research team. Data were processed and ana-
lyzed in R environment (24), using package AgimicroRNA
(27) for processing microarrays and limma (28) for differen-
tial analysis. Thus, the workflow would be: (i) Preprocess-
ing microarray using background method ‘half ’, which es-
tablishes a value for negative data. (ii) Quantile normaliza-
tion (iii) and default filtering method removing control and
non-quality probes. (iv) An experimental Bayes moderated
t-statistics test was carried out from limma package in order
to observe differential expression in such data.
Putative binding of NF-kB motifs
Possible occurrence of NF-kB subunit binding motifs in the
region comprising 1000 bp upstream and 1000 bp down-
stream with respect to TSS was inspected using TRANS-
FAC matrices. The matches of the sequences against the
set of TRANSFAC matrices were performed using R envi-
ronment, specifically the functions countsPWMandmatch-
PWM contained in the Bioconductor package Biostrings.
Graphics and heatmaps
All graphs were created using Prism5 Graphpad. Heatmaps
were generated from the expression data using the Genesis
program from Graz University of Technology.
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RESULTS
Screening of miRNAs during EBV-mediated conversion of
RBLs to LCLs
To investigate the participation and role of miRNAs in
EBV-mediated transformation of RBLs we first performed
miRNAprofiling with a qPCR-based panel containing over
375 miRNAs. The analysis included CD19+ samples before
and after EBV infection, once they had become LCLs. For
this analysis, we performed two independent sets of exper-
iments with two forms of the EBV, the B95.8 strain and
the 2089 form of EBV that infects B cells very efficiently
(16), performing both in duplicate. Analysis of the results
showed significant changes in expression of 34 miRNAs
(Figure 1A and Supplementary Table S3). Remarkably, we
observed predominant downregulation of miRNA expres-
sion. Specifically, 24 miRNAs displayed significant down-
regulation (includingmiR150, miR199a-5p, miR-223, miR-
28-5p, miR451), whereas only 10 miRNAs became upregu-
lated (including miR-551b, miR-34a, miR-155, miR-193b,
miR-365).
Several of the upregulated and downregulated miRNAs
have been previously described as being involved in the
transformation of B cells or in lymphomagenesis. For in-
stance, miR-155 is overexpressed during the acquisition
of EBV-mediated latency III (29,30), and selective inhibi-
tion of miR-155 function specifically inhibits the growth of
LCLs and DLBCL (31). Also, miR-34a has been shown
to be strongly induced by EBV infection and expressed in
many EBV and Kaposi’s sarcoma-associated herpesvirus-
infected lymphoma cell lines (10) and its inhibition impairs
the growth of EBV-transformed cells. Of the downregulated
miRNAs we identified miR-150, previously described as
displaying an extremely low level of expression in Burkitt
lymphoma cells and as inducing differentiation when ec-
topically expressed in Burkitt lymphoma lines (32).
We then performed qRT-PCR with specific LNA probes
to test individual expression changes of those miRNAs dis-
playing the largest changes between RBL and LCL, con-
sidering their potential relevance in the transformation pro-
cess based on previous data. Comparing the levels of these
miRNAs between RBLs and LCLs confirmed the results
obtained in the high-throughput screening (Figure 1B). To
determine the dynamics of changes in expression of these
miRNAs we used the 2089 EBV strain (16), given that this
strain yields a high level of infection and over 90% of B cells
are positive for EBV transcription factor EBNA-2 a few
hours after being exposed to the virus. Time-course anal-
ysis of expression showed that several of the miRNAs dis-
played changes even 24 h post-infection (for instance, miR-
155 and miR-34a), before proliferation had started (Figure
1C), indicating that at least changes in these miRNAsmight
be related to the activation process or initial transformation
steps.
To test the specificity of the changes in miRNA expres-
sion associated with EBV-mediated proliferation as well as
the potential role of EBV proteins we screened in three
additional conditions. First, we screened for B cells stim-
ulated with IL-4 and CD40L, given that EBV-mediated
transformation and B cell activation share common path-
ways (33). We found similar levels of cell activation, mea-
sured by cytometry analysis of the CD86 surface marker in
IL-4/CD40L-stimulated cells and EBV-infected B cells (re-
sults not shown, but similar to those previously shown, see
(9)). In parallel, we stimulated B cells with two recombinant
forms of EBV in which the LMP-1 and EBNA-2 genes, the
two best characterized EBV-encoded proteins, are deleted.
Under these conditions, cells undergo a few divisions but
do not acquire the capability of unlimited growth. Compar-
ison of the miRNA expression levels of these three sample
sets yielded similar profiles to those obtained with wild-type
EBV (Figure 1D and Supplementary Table S4). In all cases,
we observed a very similar profile for the set of upregulated
miRNAs. In the case of downregulated miRNAs, we ob-
served more variability, but in general the majority of miR-
NAs displayed changes in the same direction than the ones
observed for wild-type EBV. These results suggest that all
four conditions share a common pathway. It is well known
that NF-kB is a common pathway for both IL-4/CD40L-
stimulation and EBV infection, making it a strong candi-
date, even as a direct transcriptional regulator for some of
them, to be that responsible for the changes observed in the
panel of miRNAs. In fact, some of the misregulated miR-
NAs, like miR-155 (34), have previously been associated
with the NF-kB pathway. It is also known that EBNA-1-
and LMP-1-deficient EBV can still make use of the NF-kB
pathway through LMP-2A (6). We also performed individ-
ual qRT-PCR analysis of the top upregulated and downreg-
ulated miRNAs at 24 h and 7 days post-infection of sam-
ples generated with wild-type EBV, EBNA-2- and LMP-1-
deficient viral particles and samples generated through IL-
4/CD40L activation. This enabled us to confirm that all
four conditions have very similar effects on the changes that
these miRNAs underwent (Figure 1E).
Transcriptional and epigenetic control of miRNAs associated
with EBV-mediated transformation of B cells
To determine whether miRNA expression changes ob-
served during RBL to LCL conversion are a consequence
of transcriptional regulation or due to modulation of
miRNA stability, we determined by qRT-PCR the levels
of long miRNA precursors, termed primary miRNAs (pri-
miRNAs), during this process. The analysis of these pre-
cursors revealed similar dynamics in the changes to mature
miRNAs levels, and most of the pri-miRNAs showed in-
creased or decreased levels even before 24 h, indicating that
these miRNAs are subject to transcriptional activation con-
trol (or repression). In the case of miR-199a we checked the
pri-miRNAs corresponding to its two genomic locations,
and only miR-199a1 (located in chromosome 19) displayed
the expected changes in expression, discarding the other one
as responsible for the observed changes in the mature form
of this miRNA (Figure 2A).
The existence of transcriptional control in mediating the
observed changes in miRNA expression suggests the po-
tential participation of epigenetic mechanisms, together
with changes in association of transcription factors. Pre-
vious results from our team had demonstrated the exis-
tence of DNA demethylation events in association with
EBV-mediated transformation (8) as well as changes in his-
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Figure 1. MicroRNA expression profiling during RBL-to-LCL transformation. (A) Heatmap including the data for the two RBL/LCL pairs of samples
showing differential expression of miRNAs for each of the EBV systems (B95.8 EBV strain, left, and 2089 EBV strain, right). Only those miRNAs with
an FC > 2 or FC < 0.5 were selected. Similar patterns of miRNA expression changes were obtained in the two situations. (B) Individual analysis of the
top five upregulated and downregulated miRNAs upon B95.8 EBV infection using LNA probes and qRT-PCR. (C) Time-course analysis of the miRNA
expression changes in the top upregulated and downregulated miRNAs using LNA probes and qRT-PCR. In this case we used the 2089 EBV strain, which
has a very high yield of infection. (D) Heatmap showing differential expression of miRNAs between B cells after four different treatments (infected with
wild-type 2089 EBV, EBV deficient for LMP-1, EBV deficient for EBNA-2 and stimulated with IL-4 /CD40L) with respect to resting B cells. The data
represented in the heatmap correspond to the average of the fold change for each case. Similar patterns of miRNA expression were found in all samples.
(E) Individual analysis of previously selected miRNAs using LNA probes and qRT-PCR for all four situations, as in the previous section.
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Figure 2. Transcriptional and epigenetic control of miRNAs in EBV-mediated transformation of RBLs. (A) qRT-PCR analysis of miRNA precursors
(primary miRNAs) for the top five upregulated and downregulated miRNAs at different times (3 h, 1, 3, 7 days and LCLs) following infection of RBLs
with EBV (2089 EBV strain). (B) Scheme depicting the genomic localization of selected miRNAs. Each empty square represents the mature form of a
given miRNA. TSSs are indicated with an arrow. TSS locations were predicted using miRStart (http://mirstart.mbc.nctu.edu.tw/) (25). (C) Analysis of
DNA methylation changes in CpGs by pyrosequencing. For each miRNA 2–8 consecutive CpGs were analyzed in RBLs and LCLs. The location of the
analyzed CpGs is represented on top in relation with the TSS (indicated by an arrow). (D) Comparison of the ChIP-seq profiles for H3K4me3, H3K27me3
and H3K9me3 between RBLs and LCLs for all miRNAs of our study. A window of 5000 bp was inspected. The values correspond to the ratio between
LCL and RBL of the average value using 50 bp segments within the 5000 bp window of each miRNA. Log2 values are represented. (E) Examples of the
comparison of the ChIP-Seq profiles of two histone modifications (H3K4me3, active transcription; H3K27me3, repression) for one upregulated miRNA
(miR-193b/miR-365) and one downregulated miRNA (miR-451) in RBLs and LCLs.
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tone modifications like H3K27me3 and H3K9me3 (9). We
therefore tested the epigenetic profile around the TSS of
several upregulated and downregulated miRNAs. To this
end we first determined the TSS of all miRNAs display-
ing expression changes using miRStart (Figure 2B) (25).
We then investigated the possible existence of DNA methy-
lation changes near the TSS using BPS. For instance, for
miR-155, one of the upregulated miRNAs, we found no de-
tectable levels of methylation in the four CpG sites near its
TSS in either RBLs or LCLs (Figure 2C). Other examples
of miRNAs tested for methylation near the corresponding
TSS included downregulated miRNAs like miR-223, miR-
199a and miR-150, in which we observed variable levels of
DNA methylation but no differences were found between
RBL andLCL (Figure 2C). In summary, we did not observe
any changes inDNAmethylation at the TSS associatedwith
miRNAs.
We also tested the levels of histone modifications like
histone H3K4me3, H3K27me3 and H3K9me3, which are
associated with transcriptional activation and repression,
respectively. To this end, we compared ChIP-seq data be-
tween RBLs and LCLs (GSE19465 for RBLs, ENCODE
data for GM12878 for LCLs, described in detail in the Ma-
terials and Methods). We noted changes in these marks
that were compatible with those observed in the expres-
sion of these miRNAs. A general analysis across all up-
and downregulated miRNAs revealed that both H3K4me3
and H3K27me3 show significant changes that are consis-
tent with the change in expression (Figure 2D and Sup-
plementary Table S5). Specifically, upregulated miRNAs
generally displayed an increase in histone H3K4me3 and
a decrease in histone H3K27me3, whereas downregulated
miRNAs exhibited higher levels of histone H3K27me3 and
lower levels of histone H3K4me3 (Figure 2D). In contrast,
changes in H3K9me3 are less associated with the miRNA
expression changes. For instance, we observed that miR-
NAs like miR-193b/miR-365, which become upregulated
during RBL-to-LCL transformation, display an increase in
H3K4me3 and a decrease in H3K27me3 (Figure 2E). For
downregulated miRNAs, such as miR-223, miR-150 and
miR-451 (Figure 2E and Supplementary Figure S1), the de-
crease in H3K4me3 was more evident than the increase in
H3K27me3. In summary, our findings reinforce the notion
of the existence of mechanisms that control gene transcrip-
tion, which might complement the effects of direct control
by transcription factors, including those involved in theNF-
kB pathway.
NF-kB is directly involved in regulation of both upregulation
and downregulation of miRNAs in RBL-to-LCL transforma-
tion
To explore the potential involvement of the NF-kB path-
way in the observed changes in miRNAs during the trans-
formation of B cells we did several analyses. First, we in-
vestigated the enrichment of the consensus sites for NF-kB
subunits (p65, p50, c-rel, etc.) in a window of 1000 bp up-
stream and downstreamwith respect to the TSS ofmiRNAs
(determined from themiRStart database) (25). This showed
these consensus binding sites to be present in the majority
of miRNA TSSs (Supplementary Figure S2). We then de-
termined the presence of peaks of p65 subunit of NF-kB
and RNA pol II binding from ChIP-seq experiments in the
proximity of the TSSs of all miRNAs using public data sets
(see Supplementary Table S2). This revealed the presence
of p65 peaks in 7 out of 10 upregulated miRNAs and 11
out of 24 downregulated miRNAs, indicating that p65 NF-
kB is physically associated with the TSS of both upregu-
lated and downregulated miRNAs and, therefore, perhaps
involved both in activation and repression of miRNAs (Fig-
ure 3A and Supplementary Figure S3). To further explore
the involvement of theNF-kB pathway in the activation and
repression of these miRNAs, we treated RBLs with two dif-
ferent NF-B inhibitors: Bay 11–7082 and sodium auroth-
iomalate (SATM) and investigated the effects on the expres-
sion changes on the aforementioned miRNAs. Bay 11–7082
has been commonly used as a specific NF-kB inhibitor, al-
though recent data have questioned its specificity (35,36).
SATM forms gold adducts with the cysteine residues of
IKK (37) although its use as a NF-kB inhibitor has been
more restricted. We first set up the concentration for each
inhibitor by using LCLs and awide range of concentrations.
We selected 10Mfor Bay 11–7082 and 500Mfor SATM.
Both compounds were able to impair changes in expression
of upregulated and downregulated miRNAs, although Bay
11–7082 has a higher effect (Supplementary Figure S4 and
Figure 3B), reinforcing the notion of the role of this path-
way in mediating misregulation of these miRNAs.
We then confirmed the presence of p65NF-kB at the TSS
of these miRNAs, by performing ChIP assays with anti-p65
antibodies in CD19+ cells before and 72 h after infection
with EBV and investigated the association of p65 at the ge-
nomic sequence around the TSS of both miRNAs that be-
come upregulated (miR-155, miR-34a and miR-193b) (34)
and downregulated (miR-199a, miR-150 and miR-451), fo-
cusing on sequences that display binding motifs for NF-kB.
We also used the TSH2B as negative control. Interestingly,
we observed specific enrichment of p65 at 72 h after EBV
infection in both upregulated and downregulated miRNAs
genes (Figure 3C), demonstrating the EBV-dependent asso-
ciation of p65 to both sets of miRNAs. Interestingly, bind-
ing of p65 was abrogated upon treatment with the NF-kB
pathway inhibitor SATM (Figure 3C). For this and the fol-
lowing experiments we used SATM instead of Bay 11–7082,
because the latter induces cell death, as also reported by oth-
ers (38).
Finally, to test the implication of NF-kB in the histone
modification-mediated regulation of these miRNAs we per-
formed ChIP assays with the two histone modifications
which had displayed significant changes in relation with
their increase or decrease at the TSS of these miRNAs, i.e.
histone H3K4me3 and histone H3K27me3. ChIP assays
confirmed the decrease of histone H3K27me3 in miRNAs
that become upregulated and their increase inmiRNAs that
are downregulated (Figure 3D, top). In contrast, we ob-
served and increase of histone H3K4me3 in miRNAs that
become upregulated, although changes in miRNAs that be-
come downregulated were less strict (Figure 3D, bottom).
These changes were partially or totally abrogated in the
presence of NF-kB pathway inhibitor SATM (Figure 3D).
These changes were not observed at control genes that are
not targeted by p65 (Figure 3D).
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Figure 3. NF-kB dependence of miRNA expression changes. (A) ChIP-Seq analysis for NF-kB p65 and pol II in LCLs around the TSS of selected
miRNAs, one upregulated (miR-155) and two downregulated (miR-34a and miR-451). (B) Effects of one of the NF-B pathway inhibitors, SATM (at 500
M), in the levels of selected upregulated and downregulated miRNAs in a time-course analysis of B cells infected with EBV. (C) ChIP assays for the above
miRNAs showing the binding of the NF-kB p65 and pol II in B cells infected with EBV after 3 days and once they have become LCLs, as well as the effect
following treatment with NF-kB pathway inhibitor SATM at two concentrations (500 M and 1 mM). (D) ChIP assays demonstrating changes in histone
H3K4me3 and histone H3K27me3 at the TSS of upregulated and downregulated miRNAs, as well as the effect following treatment with 1 mM SATM.
(E) Effects of siRNA on p65 levels in B lymphocytes following transfection and EBV infection after 2 and 3 days, as analyzed by qRT-PCR (relative to the
combined levels of the RPL38 and HPRT1 genes) and western blot (-actin as loading control). Control samples correspond to B lymphocytes transfected
with a control siRNA and were also infected with EBV. (F) Effect of p65 depletion on the expression changes of selected upregulated and downregulated
miRNAs in a time-course analysis of B cells infected with EBV. (G) Effect of p65 depletion on their recruitment near the TSS of miRNAs, as demonstrated
by ChIP assays.
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Given the limited specificity of the two above inhibitors,
as an unequivocal test of a potential causal relationship
between NF-kB and miRNA expression changes in EBV-
mediated B lymphocyte transformation, we investigated the
consequences of ablating p65 expression in RBLs. To this
end, we downregulated p65 levels in RBLs using transient
transfection experiments with an siRNA that targets exon
11 of p65. In parallel, we used a control siRNA. Follow-
ing transfection we infected both control siRNA- and p65
siRNA-treated cells with EBV. Under these conditions, we
used qRT-PCR and western blot to check the effects on p65
levels 48 and 72 h after EBV infection. By this means, we
were able to confirm that the level of p65 downregulation
was close to 40% at 72 h at both mRNA and protein lev-
els (Figure 3E). We examined the expression levels of these
miRNAs following p65 depletion and found that both up-
regulation and downregulation of the miRNAs was par-
tially impaired following siRNA-mediated p65 depletion
(Figure 3F). We confirmed that siRNA-mediated downreg-
ulation of p65 resulted in decreased binding of p65 to the
miRNAs-associated TSS (Figure 3G).
Together, our findings indicate that NF-kB is involved in
both activation and repression of miRNAs, and that this
process is mediated by changes in histone H3K4me3 and
histoneH3K27me3.Most of the reports have demonstrated
a role for NF-kB as a transcriptional activator, although it
has also been reported that it can act as a repressor (39).
Analysis of miRNA expression in B cell lymphomas
As indicated, the pathogenic role of EBV and lymphomas
is well established for Burkitt, Hodgkin and DLBCL, al-
though the latter two have a less strict association than
Burkitt lymphomas. On the other hand, of the lymphoid
malignancies, those most clearly associated with NF-B
pathway are the ABC subgroup of DLBCL (40), Hodgkin
lymphomas, primary mediastinal B cell lymphomas, gas-
tric MALT lymphomas and multiple myeloma. Given these
two facts, we decided to explore the relationship between
the miRNAs whose expression changes in EBV-mediated
transformation of RBLs and those obtained when compar-
ingDLBCLs with normal LN, which are enriched in B cells.
To this end, we first compared the expression status of the
selection of the upregulated and downregulated miRNAs
analyzed above and compared a cohort of 18 samples corre-
sponding to DLBCL and 17 samples corresponding to con-
trol LN (Figure 4A). This comparison revealed that miR-
155 is also upregulated in DLBCLs compared with LN and
that miR-150, miR-199 and miR-28 are significantly down-
regulated inDLBCLwith respect to LN. In parallel, we also
used the miRNA expression data for DLBCL obtained by
Martin-Pe´rez et al. (26); andLN (GSE23026) from the same
research team and obtained the expression changes between
these two groups. This comparison allowed us to confirm
the data obtained by individual analysis of selected miRNA
and identified additional miRNAs displaying a significant
change in expression when comparing DLBCLs with LN
similar to that observed during the EBV-mediated trans-
formation of RBLs (Figure 4B and Supplementary Table
S6). We also performed this analysis by separating the two
DLBCL subgroups, ABC DLBCL and GCDLBCL. Inter-
estingly, for the miRNAs that are misregulated in response
to EBV-mediated transformation, we observed similar pat-
terns of miRNA expression for both groups (Supplemen-
tary Figure S5).
Functional effects of miRNAs in EBV-mediated transforma-
tion of B cells and in DLBCLs
Changes in the levels of miRNAs are likely to affect the
levels of their targets. To identify miRNA targets, we re-
trieved a list of putative targets using miRWalk (41), which
contains prediction databases like TargetScan (42), miRDB
(43) and others, as well as information about validated tar-
gets. We then linked the list of potential targets with expres-
sion data from RBL versus LCL comparisons (GSE30916)
(23) and with expression data corresponding to a cohort of
17 DLBCL samples and 7 control LN (44), assuming an
inverse relationship between the levels of a given miRNA
and the expression levels of its targets. To select targets we
chose those predictedwith aminimumof three hits in differ-
ent databases from miRWalk and at least 2-fold change for
overexpressed genes or 0.5-fold change for downregulated
genes (Figure 5A and Supplementary Table S7).We concen-
trated our efforts on those miRNAs for which we had ob-
served changes in the same direction when comparing RBL
versus LCLs and DLBCL versus LN, i.e. miR-155, among
the tested upregulated miRNAs, and downregulated miR-
NAs mir-199a-5p, miR-28-5p and miR-150. We observed a
number of putative targets relevant to B cell transformation.
For instance,MKI67 and TRAF1 are targeted by miR-150,
miR-199a-5p and miR-28-5p.MKI67 encodes for a protein
that is considered a classical marker for cell proliferation
(45) and TRAF1 is a key factor in EBV-mediated transfor-
mation (46) and in lymphomagenesis (47). Other examples
include MCM10 and CCND1 also targeted by miR-199a-
5p, PBK, that promotes tumour cell proliferation through
p38 MAPK activity (48) that is targeted by miR-28-5p and
cyclin genesCCND1 andCCND2 targeted by miR-150. We
confirmed changes in expression of these targets over a time
course in B cells following EBV infection (Figure 5B).
To confirm the direct effects of the aforementioned miR-
NAs on the levels of their putative targets, we focused on the
downregulated miRNAs. We transfected mimics for miR-
150, miR-199 and miR-28 in LCLs. The transfection effi-
ciency of mature miRNAs was assessed by FACS analysis
using control fluorophore-labeled miRNAs, which revealed
that over 88% of LCLs became positive (Figure 5C). qRT-
PCR of each miRNA showed peak high expression levels
with respect to untransfected LCLs at 24 and 48 h (Figure
5C). We then investigated the effects on the mRNA levels
of their targets. Several of these targets had significantly re-
duced mRNA levels following mimic transfection (Figure
5E), indicating a role of the changes in these miRNAs with
respect to their levels.
Finally, we tested the effects of thesemiRNAs on cell pro-
liferation and apoptosis. We first tested the impact of trans-
fecting DLBCL cell line MD901 with mimics for miR-155
(upregulated during EBV-mediated B cell transformation),
miR-150, miR-199 andmiR-28 (downregulated) measuring
incorporation of BrdU or tritiated thymidine. We were un-
able to observe any significant effect on cell proliferation
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Figure 4. Comparison of the miRNA expression changes in primary DLBCLs. (A) Individual analysis of selected miRNAs in DLBCL and LN (negative
control) cases using LNA probes and qRT-PCR. EBV positive and negative DLBCL cases are indicated. Fold changes were statistically significant for one
upregulated miRNA (miR-155) and three downregulated miRNAs (miR-199a, miR-28 and miR-150) (***P < 0.0001). (B) Comparison of the miRNA
expression data obtained by using a high-throughput analysis for miRNAs in a cohort of DLBCLs (26) and controls (LN) (GSE23026). Black and light
gray bars correspond to upregulated and downregulated miRNAs respectively from the RBL versus LCL comparison.
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Figure 5. Expression changes of miRNA targets in EBV-mediated transformation of B cells and DLBCL. (A) Heatmap including expression data of
putative targets in the RBL versus LCL and DLBCL versus LN comparisons. Represented targets include those predicted for at least 3 of 10 prediction
algorithms (DIANA-mT,miRanda,miRDB,miRWalk, RNAhybrid, PCTAR4, PICTAR5, PITA,RNA22, TargetScan) in themiRWAlk program. Putative
targets were comparedwith expression data frommicroarray data ofRBL versus LCL (FC> 2,P< 0.05) andDLBCLversus LN (FC> 1.3,P< 0.05). Only
targets common to both processes were represented. (B) Individual analysis for selected targets using qRT-PCR and a time-course series of B cells following
EBV infection. (C) Efficiency of the experiments of miRNAmimic transfections. (D) Summary table indicating the miRNA/targets analyzed in functional
experiments. (E) Effects of the introduction of mimics in LCLs for selected miRNAs (miR-150, miR-199a-5p and miR-28-5p) in the expression levels of
their targets. (F) Analysis of tritiated thymidine and BrdU incorporation on MD209 cells following transfection with selected miRNA mimics (miR-155,
miR-150, miR-199a-5p and miR-28-5p) and a control miRNA mimic (G) Analysis of apoptosis levels following transfection with the aforementioned
selected miRNA mimics and measured by TMRM fluorescence.
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(Figure 5F). In contrast, when we investigated the effects on
induced apoptosis following transfection with thesemimics,
we observed that ectopic expression of miR-155 increased
the resistance to apoptosis, whereas overexpression of miR-
150, miR-199 and miR-28 increased the levels of apoptotic
cells (Figure 5G), indicating that their downregulation fol-
lowing infection with EBV reduces the propensity to un-
dergo apoptosis during EBV-mediated transformation of B
cells.
DISCUSSION
Our results provide evidence of the existence of widespread
changes of miRNA expression in association with EBV-
mediated transformation of RBLs. It is notable that down-
regulation of miRNAs is predominant with respect to
miRNA overexpression. In addition, comparison of these
results with those obtained by activating and inducing pro-
liferation with the T cell-derived mitogens CD40L and IL-
4, as well as with EBV particles deficient for EBNA-2 and
LMP-1, suggests that the process is driven by a pathway that
is common to all four situations, i.e. the stimulation of the
NF-kB pathway. This hypothesis is reinforced by our find-
ings on the presence of binding motifs of NF-kB subunits,
NF-kB p65 ChIP-seq data near the TSS of miRNAs, ChIP
assays on selected up- and downregulated miRNAs, as well
as results about the inhibition of this pathway and the ef-
fects on miRNA levels and reduced p65 binding. Several
of the miRNA targets are related to cell transformation or
proliferation. In addition, the significant overlap between
the miRNA expression changes in EBV-related B cell trans-
formation and DLBCL versus LN reinforces the notion of
the relevance of this pathway to B cell transformation and
especially in lymphomagenesis.
Several studies have previously addressed the effects of
EBV infection on the miRNAs of host B cells. Changes in
various miRNAs have been described, including upregula-
tion of miRNAs like miR-155 (29,30) and miR-34a (10),
and downregulation of miRNAs like miR-150 (32). Our
own data have shown changes in these miRNAs as well.
The global analysis shows that miRNA downregulation is
predominant with respect to miRNA upregulation. miR-
NAs have negative effects on gene expression, so an overall
decrease in miRNA levels suggests that some of the con-
straints for gene repression are relaxed. This observation
is compatible with the general notion that transformation
of RBLs to LCLs results in overexpression of many genes.
These data are also consistent with our own observations
about epigenetic control when analyzing DNAmethylation
and histonemodification changes during the EBV-mediated
transformation of B cells. In the case of DNA methyla-
tion we found that hypomethylation, and not hypermethy-
lation, occurs during this process (8) again reinforcing the
idea of relaxation of gene control. For histonemodifications
and accessibility to endonucleases we also observed changes
that are compatible with increased gene expression, specif-
ically a decrease in heterochromatic histone modifications
and increased accessibility (9).
Our findings also indicate that the changes observed for
RBL transformedwithwild-type EBVare common to other
similar situations. We noted a similar pattern of miRNA
misregulation in B cells stimulatedwith IL-4/CD40L and in
B cells infected with EBV deficient for LMP-1 and EBNA-
2, the best characterized EBV proteins. In the first case, cells
are stimulated to proliferate at a similar rate to cells infected
with EBV. In B cells infected with these defective EBV par-
ticles, the initial steps toward transformation take place but
proliferation rates are much lower. However, all situations
share the stimulation of the NF-kB pathway and the com-
monalities in the misregulation of miRNAs suggest the role
of this pathway. Although our study has focused on the ele-
ments within the canonical pathway, EBV and CD40L also
stimulated the non-canonical pathway (49,50), which may
also be involved in miRNA misregulation. It is then likely
that LMP-1-deficient EBV make use of the non-canonical
NF-kB pathway and this could explain stimulation of com-
mon sets of miRNAs. This had been previously demon-
strated for miR-155 (34), in which the two binding sites at
the miR-155 promoter recruit NF-kB, which is stimulated
by LMP-1. In the case of EBNA-2- and LMP-1-deficient
EBV particles, it is thought that stimulation of the NF-
kB pathway occurs through LMP2A (6). The direct role of
NF-kB in the regulation of these miRNAs is supported by
the results obtained with both ChIP-seq data and individ-
ual ChIP assays and the observation that inhibitors for the
NF-kB pathway impair both miRNA expression changes,
as well as the binding of p65 and the changes in histone
modifications at the mRNA genomic sites during the trans-
formation of RBL with EBV. The implication of the NF-
kB in directly targeting miRNAs has previously reported
(34), however, to the best of our knowledge, our study is the
first evidence demonstrating a direct role of this pathway
in both targeting up- and downregulated miRNAs, as well
as the finding of direct changes in the histone modification
marks around the TSS of both groups of miRNAs. Previ-
ous studies have shown the ability of EBV and LMP-2 to
upregulate DNMT3b and drive hypermethylation in gastric
cancer (51), however, during infection of B cells from pe-
ripheral blood, we have been able to identify demethylation
events (8) and there are no changes at the miRNA genomic
sites.
The NF-kB pathway is relevant in the context of EBV-
transformation of B cells and is considered to be a ma-
jor pathway in lymphomagenesis, particularly in certain
types of lymphomas, including DLBCL, which are also
known to be associated with EBV infection. Comparing
the miRNA displaying significant change during the EBV-
mediated transformation of RBLs and those from the DL-
BCL and LN analysis revealed striking resemblances, sug-
gesting that the type of changes in miRNAs are common
to the two processes. This also applies to large sets of the
predicted targets for these miRNAs, reinforcing the notion
of the relevance of EBV and NF-kB in the pathogenesis of
DLBCL. Earlier studies have shown that ABC DLBCL are
more dependent on theNF-kB pathway (40). In this sense, it
was relevant to compare the miRNA expression profiles of
ABCDLBCL versus those fromGCDLBCL. However, we
did not observe a significant difference between these two.
Recent studies have demonstrated that mutations in NF-kB
related genes account for deregulation of the NF-kB path-
way also in GC DLBCL (52).
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There is increasing evidence of a role for miRNAs in
proper B cell differentiation and in relation with the patho-
genesis of B cell lymphomas (13). Interestingly, among the
misregulated miRNAs in our model, i.e. the EBV-mediated
transformation of B cells, there are several well studiedmiR-
NAs known for their relevance in the biology and cell cy-
cle within the B cell compartment. For instance, miR-150
is associated with B cell differentiation and its upregula-
tion is negatively associated with the expression of C-MYB
(53).MiR-34a, one of the top upregulatedmiRNAs in EBV-
mediated B cell transformation, is known to target Foxp1
required for B cell differentiation (54). In this context, miR-
155 has also been associated with B cell differentiation (55).
Quiescent differentiated B cells have a restricted transcrip-
tion program in which only a limited set of genes (ubiqui-
tously expressed and cell type-specific genes) are expressed.
This progressive restriction of the transcription program, is
well known to occur during differentiation. EBV-mediated
transformation could therefore be viewed as a process in-
verse to that occurring during differentiation, and some of
the mechanisms involved are likely to act in an opposite di-
rection to those driving differentiation. Therefore, the acti-
vation of the aforementioned miRNAs, and the downreg-
ulation of a large number of miRNAs leading to the loos-
ening of repression of many genes would be consistent with
the type of changes occurring in transformed B cells. Our
analysis of miRNA targets has led to the identification of
genes that may play a key role in the transformation pro-
cess and in maintaining the phenotype in lymphoma cells,
including MKI67 and TRAF, targeted by at least three of
the downregulatedmiRNAs, and others likeCCND1, STIL
and PBK targeted by miR-150, miR-199a-5p and miR-28,
respectively. Overall, our findings indicate a close relation-
ship in the miRNA-mediated acquisition of the phenotype
in B cells and a connection between the transformation pro-
cess and the phenotype in lymphomas.
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